Immunomodulation therapy in colorectal carcinoma

Yip, Desmond; Strickland, A. H.; Karapetis, Christos S.; Hawkins, Cynthia; Harper, P.G.

doi:10.1053/ctrv.1999.0160

Cited by 20 publications

(5 citation statements)

References 168 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Many non-specific immunomodulatory agents such as levamisole, CIM, alpha interferon, n-3 fatty acids, polysaccharide K (PSK), supplementary diet with glutamine, arginine and omega-3-fatty acids, and Bacillus Calmette-Guerin (BCG) have been tried [1][2][3][4] . CIM is a type 2 histamine receptor antagonist widely used for the treatment of peptic ulcers.…”

Section: Introductionmentioning

confidence: 99%

Perioperative cimetidine administration promotes peripheral blood lymphocytes and tumor infiltrating lymphocytes in patients with gastrointestinal cancer: Results of a randomized controlled clinical trial

Cai¹,

Bai²,

Yuan³

et al. 2004

WJG

View full text Add to dashboard Cite

AIM:To study the effects of perioperative administration of cimetidine (CIM) on peripheral blood lymphocytes, natural killer (NK) cells and tumor infiltrating lymphocytes (TIL) in patients with gastrointestinal (GI) cancer. METHODS:Forty-nine GI cancer patients were randomized into treatment group, who took CIM in perioperative period, and control group, who did not take the drug. The treatment was initiated 7 days before operation and continued for 10 days after surgery. At baseline examination before operation, on the 2nd and 10th postoperative days, total T lymphocytes, T helper cells, T suppressor cells, and NK cells in peripheral blood were measured respectively by immunocytochemical method using mouse-anti human CD 3 , CD 4 , CD 8 and CD 57 monoclonal antibodies. Blood samples from 20 healthy volunteers were treated in the same way as normal controls. Surgical specimens were examined during routine histopathological evaluation for the presence of TIL in tumor margin. Immunohistochemical study was performed to measure the proportion of T and B lymphocytes in TIL population. T and B lymphocytes were detected respectively using mouse-anti-human CD 3 and CD 20 monoclonal antibodies. RESULTS:In comparison with normal controls, both the treatment and control groups had decreased T cells, T helper cells and NK cells at baseline. In control group, total T cells, T helper cells and NK cells declined continuously with the disease progression and the decrease became more obvious after operation. From baseline to the 2nd postoperative day, the proportion of total T cells, T helper cells, and NK cells went down from 60.5±4.6% to 56.2±3.8%, 33.4±3.7% to 28.1±3.4%, and 15.0±2.8% to 14.2±2.2%, respectively. On the other hand, there were significant improvements in these parameters after CIM treatment. On the 10th postoperative day, the treatment group had significantly higher percentages of total T cells, T helper cells and NK cells than control group. Moreover, CIM treatment also boosted TIL response, as was reflected by findings that 68% (17/25) of the patients in treatment group had significant TIL responses and only 25% (6/24) of the cases had discernible TIL responses (P<0.01). CONCLUSION:Perioperative application of CIM to GI cancer patients could help restore the diminished cellular immunity induced by tumor burden and surgical maneuver. The drug could also boost TIL responses to tumor. These effects suggest that the drug be used as an immunomodulator for GI cancer patients.

show abstract

Section: Introductionmentioning

confidence: 99%

Perioperative cimetidine administration promotes peripheral blood lymphocytes and tumor infiltrating lymphocytes in patients with gastrointestinal cancer: Results of a randomized controlled clinical trial

Cai¹,

Bai²,

Yuan³

et al. 2004

WJG

View full text Add to dashboard Cite

show abstract

“…Research has shown that in the animal model of colorectal cancer and in patients with colorectal cancer patients, antigen-specific cytotoxic T lymphocytes (CTL) are induced [ 23 ]. Therefore, colorectal cancer is immunogenic, but it is possible that colorectal cancer still develops for the following reasons: (1) in patients with colorectal cancer where expression of the histocompatibility leukocyte antigen (HLA)-I was decreased or absent [ 24 ], the lack of antigen presentation by the tumor cells led to the induction of CTL responses. (2) Mutations in peptide transporting molecules (TAP) may also affect the presentation of T cell epitopes [ 25 ].…”

Section: Discussionmentioning

confidence: 99%

Growth of Human Colorectal Cancer SW1116 Cells Is Inhibited by Cytokine-Induced Killer Cells

Wang

Dai

et al. 2011

Clinical and Developmental Immunology

View full text Add to dashboard Cite

Previous reports have suggested that treatment with cytokine-induced killer (CIK) cells may benefit patients with various types of tumor. The aim of this study was to evaluate the antitumor effects of CIK cells against the colorectal cancer line SW1116 in vitro and in vivo. CIK cells were generated routinely from peripheral blood mononuclear cells of healthy human donors, and the number of CD3+CD56+ cells was expanded more than 1300-fold after 14-day culture. At an effector : target cell ratio of 50 : 1, the percentage lysis of SW1116 cells reached 68% in the presence of CIK cells, Experimental mice injected with SW1116 cells subcutaneously were divided randomly into four groups: untreated, 5-fluorouracil (5-FU)-treated, CIK-consecutive treated (injected once/day) and CIK-interval treated (injected once every 5 days). CIK cells were injected abdominally five times in total. Compared with the untreated group, xenograft growth was inhibited greatly by CIK treatment, to nearly the same extent as with 5-FU treatment. We demonstrated that the necrotic area in the tumor xenograft was markedly larger in the CIK-treated groups than in the other groups. These findings suggest that CIK-based immunotherapy may represent an effective choice for patients with colorectal cancer.

show abstract

“…, 1989; Forman, 1994; Holcombe et al. , 1998; Moore & Haller, 1999; Yip et al. , 2000; Zlotta & Schulam, 2000).…”

Section: Suspected Adverse Reactions In Animalsmentioning

confidence: 99%

“…Overall, the drug has relatively low toxicity (Van Cauteren et al, 1985). Levamisole is an anthelmintic drug used in animals which has also found a role in the treatment of cancer and rheumatoid arthritis in humans because of its immunomodulatory effects (Robens, 1984;Laurie et al, 1989;Forman, 1994;Holcombe et al, 1998;Moore & Haller, 1999;Yip et al, 2000;Zlotta & Schulam, 2000). In humans, it may induce adverse effects including agranulocytosis and hypersensitivity reactions (Secher et al, 1977(Secher et al, , 1978Prieur et al, 1978;Symoens et al, 1978;Runge & Rynes, 1983).…”

Section: Large Animalsmentioning

confidence: 99%

Veterinary pharmacovigilance. Part 3. Adverse effects of veterinary medicinal products in animals and on the environment

Woodward¹

2005

Vet Pharm & Therapeutics

View full text Add to dashboard Cite

Like humans, animals may experience adverse effects when treated with medicinal products. These effects may be related to the pharmacological or toxicological properties of the substances used or they may arise because of hypersensitivity. Veterinary medicinal products may also possess the ability to harm the environment. This paper reviews the potential of veterinary medicinal products to cause adverse effects in animals and on the environment.

show abstract

Immunomodulation therapy in colorectal carcinoma

Cited by 20 publications

References 168 publications

Perioperative cimetidine administration promotes peripheral blood lymphocytes and tumor infiltrating lymphocytes in patients with gastrointestinal cancer: Results of a randomized controlled clinical trial

Perioperative cimetidine administration promotes peripheral blood lymphocytes and tumor infiltrating lymphocytes in patients with gastrointestinal cancer: Results of a randomized controlled clinical trial

Growth of Human Colorectal Cancer SW1116 Cells Is Inhibited by Cytokine-Induced Killer Cells

Veterinary pharmacovigilance. Part 3. Adverse effects of veterinary medicinal products in animals and on the environment

Contact Info

Product

Resources

About